Georgia Free Industrial Zones for Medical Devices: Tax Benefits Without Compliance Shortcuts

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The tax arrangements of a Free Industrial Zone in Georgia can lower the import and circulation cost of medical devices, but they change none of the product compliance obligations. Goods handled through a zone still require registration or a classification confirmation letter, still must meet the general safety requirements of Law No. 6157-Iს of May 8, 2012, and still must carry Georgian-language labeling. Tax optimization and compliance duty are parallel lines that never cancel each other out. The legal design supports this reading: Article 2 paragraph 1 point a of the code confines mandatory safety requirements to the regulated field, which means that any device falling inside that field is regulated identically whether it sits in a zone or in customs territory. The commercial logic of using Georgia as a regional distribution node, connecting the European Union, Turkey and CIS-facing markets, remains sound, because the Caucasus market is compact but radiating. The rule for planning is simple: treat the zone as a logistics and fiscal instrument, and run the compliance track, registration, classification and labeling, in parallel from the first day of zone operations rather than as an afterthought when goods move into consumption. A written matrix mapping each stock-keeping unit to its compliance status, whether registered, covered by a classification confirmation letter or outside the regulated field, keeps the two lines visibly separate in internal approvals.

2. Legal basis

  1. Law of Georgia No. 6157-Iს of May 8, 2012 on product safety and free movement: Article 3 paragraph 1 (unhindered access of products to the market), Article 3 paragraph 2 (where no dedicated technical regulation exists, chapters two and three apply), Article 2 paragraph 1 point a (mandatory safety requirements apply only within the regulated field).
  2. Law of Georgia on Drugs and Pharmaceutical Activity, Law No. 1586 of August 10, 2009: Article 11⁴ and Article 11⁶.
  3. Law of Georgia on Health Care No. 6000 of March 21, 2008: Article 66 and Article 67 paragraph 2.
  4. Government Decree No. 278 of August 1, 2023: inspection powers of the regulatory authority over medical and pharmaceutical facilities.
  5. Practical estimate statement: the concrete tax treatment of free industrial zones, the scope of exemptions and the applicable conditions are not stated in the official provisions verified for this topic; these are tax and investment matters to be confirmed against Georgian tax law, zone management rules and the competent tax authority.

3. Expert insights

Insight one: Article 2 paragraph 1 point a determines that inside the zone is not outside the law. The provision confines national mandatory safety requirements to the regulated field; read in reverse, any product that falls within that field is subject to the same safety requirements whether it is held in a free industrial zone or in customs territory. Fiscal privilege and product safety belong to different policy domains and do not offset one another. A zone therefore offers no compliance exemption and no compliance discount: the day goods enter consumption in Georgia, registration and labeling duties attach in full. Companies that document this understanding internally avoid the most damaging planning error, namely treating the zone as a substitute for registration and discovering the gap at the first audit or market inspection.

Insight two: a free industrial zone fits best as a regional distribution node, not as a compliance shortcut. The Caucasus market is limited in size but strong in reach, linking directions toward the European Union, Turkey and the CIS. Concentrating stock in Georgia and dispatching regionally from it is a coherent commercial model. However, every consignment that crosses into Georgian territory for consumption triggers the registration and labeling obligations at that moment, and goods in the zone destined for export do not eliminate the need for compliant documentation on the export leg either. The zone changes where stock sits and how duty flows, not whether the product is regulated. Planning should therefore price the compliance track separately from the fiscal savings, so that the business case stands on logistics economics alone. A shortfall in fiscal savings then has no compliance consequences, and a compliance finding has no fiscal consequences.

Insight three: the inspection powers of Decree No. 278 reach facilities in the medical and pharmaceutical field. Where storage or sorting facilities inside the zone conduct activities that fall within the scope of medical and pharmaceutical activity, the authority can apply its inspection powers, including examinations conducted without prior notice. Placing goods inside the zone does not shield them from inspection. Operators should map their zone-based activities against the decree, prepare a document retrieval routine covering certificates, labeling samples and batch records, and brief zone staff on how to respond to an inspector. The cost of this preparation is trivial compared with the disruption of an unprepared inspection visit. The same mapping should record which documents the facility holds and who is authorized to hand them to an inspector, so that a visit ends with a clean handover rather than an open request list.

4. Practical recommendations

  1. Position the free industrial zone solution as a logistics and tax optimization tool, and keep it out of any compliance exemption argument in internal approvals and business plans.
  2. Complete the product compliance determination before starting zone operations: registration, classification confirmation letter or labeling language, all three elements confirmed, none omitted.
  3. Where storage facilities exist in the zone, prepare in advance an inspection response process and a document retrieval mechanism aligned with the powers under Decree No. 278.
  4. Refer all tax and zone matters to a Georgian tax advisor for confirmation, and run the tax workstream in parallel with the registration plan rather than sequentially after it.

5. Verification checklist

  • □ The product compliance determination has been completed covering registration, confirmation letter and labeling
  • □ The free industrial zone plan contains no compliance exemption assumptions
  • □ An inspection response process has been prepared for zone-based storage
  • □ Tax arrangements have been confirmed by a local tax advisor
  • □ The compliance plan and the tax plan are progressing in parallel

Regulatory information verified as of October 30, 2026

This English edition of the GRZAN international regulatory guide is published by GRZAN for informational purposes only. GRZAN supports manufacturers, importers and distributors with regulatory strategy, registration filings, local representative coordination, labeling review and import compliance for Georgia and other markets. For questions about this article or tailored regulatory support, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail